Angiotech Pharmaceuticals, Inc. (USA) (ANPI)
A specialty pharmaceutical and medical device company that discovers, develops and markets innovative technologies and medical products for local diseases, and for other complications.
Recs
booda7
(< 20)
Submitted: 10/23/2009 5:50:44 PM :
Start Price:
$1.53
ANPI Score:
-16.67
Great management and real product line...
Recs
Roto1177
(75.78)
Submitted: 10/1/2009 9:18:41 AM :
Start Price:
$1.76
ANPI Score:
-31.29
Insider buying
Recs
foresterbob
(98.52)
Submitted: 8/13/2009 5:20:40 PM :
Start Price:
$2.22
ANPI Score:
-64.73
Insiders are buying, at market value.
Recs
Brian7992
(< 20)
Submitted: 8/11/2009 2:29:09 PM :
Start Price:
$1.73
ANPI Score:
-36.09
Because it's cheap
Recs
sempire
(39.31)
Submitted: 8/10/2009 11:27:40 AM :
Start Price:
$1.70
ANPI Score:
-33.97
It's hard to find a good company in this sector that is not over bought, and going sideways, or one that is completely a speculative play. There looks to be some potential in ANPI.
Recs
kschmidt65
(< 20)
Submitted: 7/27/2009 1:53:30 PM :
Start Price:
$1.73
ANPI Score:
-38.10
They are in the high margin niche medical device equipment area. Insider buying in the last few months. Reporting earnings August 6th. They have several products. Approved products are: Drug-Eluting coronary stents with Boston Scientific; Vitagel surgical hemostat with Orthovita; CoSeal surgical sealant with Baxter;Medical Device Products, over 5,000 SKUs. In clinical trials Bio-Seal Biopsy Tract Plug; Option Vena Cava Filter; Ani-Infectgive HemoStream Dialysis Catheter; and MultiStem Stem Cell Therapy. Financing has been tough and they have approval to issue more stock within the next two years.
Recs
MarketOwnage
(< 20)
Submitted: 7/25/2009 12:14:01 AM :
Start Price:
$1.70
ANPI Score:
-37.06
This company is trying hard to fight through the recession. Pure speculation and just keeping my fingers cross. Before you know it, it will be in the $20 range. Please find cure for cancer.
Recs
urlosen
(< 20)
Submitted: 7/21/2009 9:25:12 AM :
Start Price:
$1.82
ANPI Score:
-45.19
This Business as a whole is booming!!! People are in no time soon predicted to stop getting sick, and this Company has recognized this!!!
Recs
Recs
Georacing96
(< 20)
Submitted: 6/22/2009 12:59:49 PM :
Start Price:
$1.63
ANPI Score:
-44.19
New technology comming onto the market. Growth in their new product.
Recs
BOSTONSTRANGLER
(79.05)
Submitted: 6/17/2009 4:17:33 PM :
Start Price:
$1.81
ANPI Score:
-50.05
VOLUME, FDA APPROVAL, BLACKSTONES INVOLVMENT, VOLUME, VOLUME VOLUME
Recs
zzlangerhans
(99.57)
Submitted: 6/15/2009 2:04:00 PM :
Start Price:
$2.07
ANPI Score:
-57.46
Angiotech survived lows of 0.1 on viability concerns after taking on enormous debt to buy American Medical. While the soundness of that decision remains questionable. the stock recently brought 25-fold return to those who bought at the low. The share price has now withdrawn substantially from recent highs even as the company is looking more financially stable with improving stent royalty revenues and approval of additional devices. As long as they don't go BK, they should rise again from here.
Recs
foolishtestarino
(< 20)
Submitted: 6/8/2009 10:43:45 AM :
Start Price:
$2.47
ANPI Score:
-66.27
asdf
Recs
EnigmaDude
(35.24)
Submitted: 6/8/2009 9:51:17 AM :
Start Price:
$2.39
ANPI Score:
-64.98
recent FDA approval
Recs
fburks
(< 20)
Submitted: 9/3/2008 9:18:13 AM :
Start Price:
$1.62
ANPI Score:
-9.38
First of all I have a very small position in this company. I based this position of my professional use of one of its products: Quills self retaining sutures. This is a great product that will probably grow in its use. I know this company has struggled with debt and reduced stent income, but I would still consider it a buy.
Recs
Fatiggy
(31.50)
Submitted: 8/1/2008 2:11:01 PM :
Start Price:
$2.01
ANPI Score:
-26.13
solid fundamentals
Recs
Toddq34
(< 20)
Submitted: 4/4/2008 1:05:57 PM :
Start Price:
$2.85
ANPI Score:
-37.55
Angiotech Pharmaceuticals, Inc. is a specialty pharmaceutical and medical device company that discovers, develops and markets technologies primarily focused on acute and surgical applications. The Company generates its revenue through the sales of medical products and components, as well as from royalties derived from sales by its partners of products utilizing certain of its own technologies. The Company operates in two segments: Pharmaceutical Technologies and Medical Products. The Pharmaceuticals Technologies segment includes royalty revenue and gross margin generated from out-licensing technology related to the drug-eluting stent and other technologies. As of December 31, 2007, the Company’s principal revenues in this segment come from royalties derived from sales by Boston Scientific Corporation (BSC) of TAXUS coronary stent systems incorporating the drug paclitaxel. The Medical Products segment includes revenues and gross margins of single use, specialty medical devices.
Recs
JCSmiley
(< 20)
Submitted: 3/10/2008 2:00:03 PM :
Start Price:
$3.03
ANPI Score:
-41.29
Anyone willing to hang on to this one for 5+ years will be rewarded! :)
Nice niche market.
Recs
jroack
(< 20)
Submitted: 1/16/2008 11:16:11 AM :
Start Price:
$3.30
ANPI Score:
-44.52
Promising product line on the expanding edge of this trend. Beaten to a pulp at this point. Time to buy.
Recs
hutch610
(< 20)
Submitted: 1/6/2008 8:28:53 PM :
Start Price:
$3.56
ANPI Score:
-44.57
Been beaten down badly and set for a rebound soon.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 39 1 2 Next »